NewAmsterdam Pharma Co N.V.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management, L.P. amended its Schedule 13G stake filing for NewAmsterdam Pharma Co N.V., per SEC accession 0001346824-26-000287. The filing updates the investment firm's previously reported beneficial ownership position in the clinical-stage biopharmaceutical company. The amendment signals a change in RA Capital's holdings, though the filing summary did not disclose the revised share count or percentage. Investors will watch for the full filing details to gauge whether the adjustment reflects a meaningful shift in the firm's conviction.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
NewAmsterdam Pharma Co N.V., RA Capital Management, L.P.